• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Murphy Canyon Acquisition Corp. (Amendment)

    2/12/24 12:51:14 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MURF alert in real time by email
    SC 13G/A 1 MurphyCanyonAcquisitionCorp.txt CONDUIT PHARMACEUTICALS INC. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No._1)* (Name of Issuer) CONDUIT PHARMACEUTICALS INC. (Formerly known as Murphy Canyon Acquisition Corp.) (Title of Class of Securities) Common Stock, $0.0001 par value per share (CUSIP Number) 20678X106 (Date of Event Which Requires Filing of this Statement) 12/31/2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) CUSIP No. 20678X106 (1) Names of reporting persons Polar Asset Management Partners Inc. (2) Check the appropriate box if a member of a group (see instructions) (a) (b) (3) SEC use only (4) Citizenship or place of organization Ontario, Canada Number of shares beneficially owned by each reporting person with: (5) Sole voting power 950,000 shares issuable upon the exercise of warrants (6) Shared voting power (7) Sole dispositive power 950,000 shares issuable upon the exercise of warrants (8) Shared dispositive power (9) Aggregate amount beneficially owned by each reporting person 950,000 shares issuable upon the exercise of warrants (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions) (11) Percent of class represented by amount in Row (9) 1.3% (12) Type of reporting person (see instructions) IA Item 1(a) Name of issuer: CONDUIT PHARMACEUTICALS INC. (Formerly known as Murphy Canyon Acquisition Corp.) Item 1(b) Address of issuer's principal executive offices: 4995 MURPHY CANYON ROAD, SUITE 300, SAN DIEGO, CA, 92123 2(a) Name of person filing: This statement is filed by Polar Asset Management Partners Inc., a company incorporated under the laws of Ontario, Canada, which serves as the investment advisor to Polar Multi-Strategy Master Fund, a Cayman Islands exempted company ("PMSMF") with respect to the shares directly held by PMSMF. 2(b) Address or principal business office or, if none, residence: 16 York Street, Suite 2900, Toronto, ON, Canada M5J 0E6. 2(c) Citizenship: Canada 2(d) Title of class of securities: Common Stock, $0.0001 par value per share 2(e) CUSIP Number: 20678X106 Item 3. [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o); [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c); [ ] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c); [ ] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); [ ] An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); [ ] An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); [ ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3); [x] A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J); [ ] Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: The Reporting Person is an investment fund manager, portfolio manager, exempt market dealer and commodity trading manager registered with the Ontario Securities Commission. Item 4. Ownership as of December 31, 2023 1. Polar Asset Management Partners Inc. (a) Amount beneficially owned: 950,000 shares issuable upon the exercise of warrants (b) Percent of class: 1.3% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 950,000 shares issuable upon the exercise of warrants (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 950,000 shares issuable upon the exercise of warrants (iv) Shared power to dispose or to direct the disposition of: 0 Item 5.Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [X]. Instruction. Dissolution of a group requires a response to this item. Not applicable Item 6. Ownership of More than 5 Percent on Behalf of Another Person. Not applicable Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reporting on by the Parent Holding Company or Control Person. Not applicable Item 8. Identification and Classification of Members of the Group Not applicable Item 9. Notice of Dissolution of Group. Not applicable Item 10. Certifications By signing below I certify that, to the best of his/her knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: February 12, 2024 POLAR ASSET MANAGEMENT PARTNERS INC. By: /s/ Andrew Ma Name: Andrew Ma Title: Chief Compliance Officer
    Get the next $MURF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MURF

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MURF
    SEC Filings

    View All

    SEC Form S-8 filed by Murphy Canyon Acquisition Corp.

    S-8 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Filer)

    1/10/24 4:43:04 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Murphy Canyon Acquisition Corp.

    424B3 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Filer)

    12/18/23 4:14:52 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Murphy Canyon Acquisition Corp.

    EFFECT - CONDUIT PHARMACEUTICALS INC. (0001896212) (Filer)

    12/18/23 12:15:16 AM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MURF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Lewis-Hall Freda C

    4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)

    12/14/23 5:16:03 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Mcnealey Jennifer Isacoff

    4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)

    12/5/23 5:20:25 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Bligh James

    4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)

    12/5/23 5:20:29 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MURF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Conduit Pharmaceuticals and Murphy Canyon Acquisition Corp. Announce Completion of Business Combination

    SAN DIEGO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Limited ("Conduit Pharmaceuticals"), a multi-asset clinical-stage disease-agnostic life science company providing an efficient model for compound development, and Murphy Canyon Acquisition Corp., a special purpose acquisition company (NASDAQ:MURF) ("MURF"), announced today the completion of the previously announced business combination (the "Transaction"). Conduit expects to commence trading on September 25, 2023, under ticker symbol "CDT" for its common stock on The Nasdaq Global Market and ticker symbol "CDTTW" for its warrants on The Nasdaq Capital Market.At the debut of trading, there will be a pro forma enterpris

    9/22/23 9:01:00 AM ET
    $MURF
    $SQFT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    Murphy Canyon Acquisition Corp. Announces Stockholder Approval of the Proposed Combination with Conduit Pharmaceuticals Limited

    SAN DIEGO, CA / ACCESSWIRE / September 20, 2023 / Murphy Canyon Acquisition Corp. (NASDAQ:MURF) ("MURF" or "Murphy Canyon"), a special purpose acquisition company, announced today that at a special meeting of the MURF stockholders (the "Special Meeting") held today, MURF's stockholders voted in favor of the proposed business combination (the "Business Combination") with Conduit Pharmaceuticals Limited ("Conduit") and the related proposals. As a result, the completion of the Business Combination is expected to occur as soon as practicable, subject to the satisfaction or waiver of remaining closing conditions. Following the completion of the Business Combination, the newly combined company wil

    9/20/23 5:40:00 PM ET
    $MURF
    $SQFT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    Presidio Property Trust, Inc. Announces Establishment of a Special Committee of the Board and Exploration of Strategic Alternatives

    SAN DIEGO, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Presidio Property Trust, Inc. (NASDAQ:SQFT, SQFTP))) (the "Company"), an internally managed, diversified real estate investment trust ("REIT"), today announced that its Board of Directors (the "Board") has established a Special Committee of the Board (the "Special Committee") to explore potential strategic alternatives focusing on maximizing stockholder value. The Special Committee is comprised solely of independent directors and is charged with exploring potential strategic alternatives, including, without limitation, a business combination involving the Company, a sale of all or part of the Company's assets, joint venture arrangements and/or

    9/13/23 8:30:00 AM ET
    $MURF
    $SQFT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    $MURF
    Financials

    Live finance-specific insights

    View All

    Conduit Pharmaceuticals and Murphy Canyon Acquisition Corp. Announce Completion of Business Combination

    SAN DIEGO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Limited ("Conduit Pharmaceuticals"), a multi-asset clinical-stage disease-agnostic life science company providing an efficient model for compound development, and Murphy Canyon Acquisition Corp., a special purpose acquisition company (NASDAQ:MURF) ("MURF"), announced today the completion of the previously announced business combination (the "Transaction"). Conduit expects to commence trading on September 25, 2023, under ticker symbol "CDT" for its common stock on The Nasdaq Global Market and ticker symbol "CDTTW" for its warrants on The Nasdaq Capital Market.At the debut of trading, there will be a pro forma enterpris

    9/22/23 9:01:00 AM ET
    $MURF
    $SQFT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    Murphy Canyon Acquisition Corp. Announces Stockholder Approval of the Proposed Combination with Conduit Pharmaceuticals Limited

    SAN DIEGO, CA / ACCESSWIRE / September 20, 2023 / Murphy Canyon Acquisition Corp. (NASDAQ:MURF) ("MURF" or "Murphy Canyon"), a special purpose acquisition company, announced today that at a special meeting of the MURF stockholders (the "Special Meeting") held today, MURF's stockholders voted in favor of the proposed business combination (the "Business Combination") with Conduit Pharmaceuticals Limited ("Conduit") and the related proposals. As a result, the completion of the Business Combination is expected to occur as soon as practicable, subject to the satisfaction or waiver of remaining closing conditions. Following the completion of the Business Combination, the newly combined company wil

    9/20/23 5:40:00 PM ET
    $MURF
    $SQFT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    Presidio Property Trust, Inc. Announces Earnings for the Quarter Ended June 30, 2023

    SAN DIEGO, CA / ACCESSWIRE / August 14, 2023 / Presidio Property Trust, Inc. (NASDAQ:SQFT)(NASDAQ:SQFTP) (the "Company"), an internally managed, diversified real estate investment trust ("REIT"), today reported earnings for its quarter ended June 30, 2023.Quarter Ended June 30, 2023, Financial ResultsNet loss attributable to the Company's common stockholders for the three months ended June 30, 2023, was approximately $1,831,889, or $(0.15) per basic and diluted share, compared to a net loss of approximately $830,212, or $(0.07) per basic and diluted share for the three months ended June 30, 2022. The change in net income attributable to the Company's common stockholders was a result of: •An

    8/14/23 5:30:00 PM ET
    $MURF
    $SQFT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    $MURF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Murphy Canyon Acquisition Corp. (Amendment)

    SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)

    2/12/24 12:51:14 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Murphy Canyon Acquisition Corp. (Amendment)

    SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)

    2/8/24 1:15:17 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Murphy Canyon Acquisition Corp. (Amendment)

    SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)

    2/2/24 4:28:59 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care